# US 2013/0254909 A1 · Synthetic regulation of gene expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0254909 A1
- Document ID: US20130254909A1
- Status: Published application
- Kind: A1
- Application number: 13/783,450
- Filed: 2013-03-04
- Published: 2013-09-26
- Earliest claimed: 2012-03-06
- Assignees: Duke University
- Inventors: Matthew S. Marengo; Mariano A. Garcia-Blanco
- Web page: https://patentgrep.com/patent/US20130254909A1

## CPC

- C12N 15/85: for animal cells
- C12N 2800/30: Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N 2840/007: cell or tissue specific
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Synthetic regulation of gene expression is provided. In some embodiments, synthetic regulatory constructs are provided. In some embodiments, a synthetic regulatory construct expresses a heterologous gene in a selected cell type. In some embodiments, methods of expressing a heterologous gene in a selected cell type are provided.

## Claims

### Claim 1

A synthetic regulatory construct comprising a cell-specific promoter, a heterologous gene, and a cell-specific exon.

### Claim 2 (depends on 1)

The construct of claim 1, wherein the cell-specific exon is excluded in the cell in which the cell-specific promoter is most active.

### Claim 3 (depends on 2)

The construct of claim 2, wherein inclusion of the exon results in the product of the heterologous gene being inactive, or no product of the heterologous gene being produced.

### Claim 4 (depends on 3)

The construct of claim 3, wherein inclusion of the exon results in a frame shift in the heterologous gene or a stop codon before or within the heterologous gene, or both.

### Claim 5 (depends on 1)

The construct of claim 1, wherein the cell-specific exon is included in the cell in which the cell-specific promoter is most active.

### Claim 6 (depends on 5)

The construct of claim 5, wherein exclusion of the exon results in the product of the heterologous gene being inactive, or no product of the heterologous gene being produced.

### Claim 7 (depends on 6)

The construct of claim 6, wherein exclusion of the exon results in a frame shift in the heterologous gene or a stop codon before or within the heterologous gene, or both.

### Claim 8 (depends on 1)

The construct of claim 1, wherein the construct further comprises a cell-specific RNA stability element.

### Claim 9 (depends on 8)

The construct of claim 8, wherein the cell-specific RNA stability element is a microRNA target sequence.

### Claim 10 (depends on 1)

The construct of claim 1, wherein the cell-specific promoter is at least 2-fold more active in a selected cell than in at least one other cell comprised in the same organism as the selected cell.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The construct of claim 1, wherein the cell is an animal cell.

### Claim 14 (depends on 13)

The construct of claim 13, wherein the cell is a mammalian cell.

### Claim 15 (depends on 14)

The construct of claim 14, wherein the mammal is selected from human, mouse, rat, dog, chimpanzee, and monkey.

### Claim 16 (depends on 1)

The construct of claim 1, wherein the cell is a plant cell.

### Claim 17 (depends on 16)

The construct of claim 16, wherein the plant is selected from a monocot and a dicot.

### Claim 18 (depends on 1)

A cell comprising the construct of claim 1.

### Claim 19 (depends on 18)

The cell of claim 18, wherein the cell is an animal cell.

### Claim 20 (depends on 19)

The cell of claim 19, wherein the cell is a mammalian cell.

### Claim 21 (depends on 20)

The cell of claim 20, which is comprised in a non-human mammal.

### Claim 22

(canceled)

### Claim 23 (depends on 18)

The cell of claim 18, wherein the cell is a plant cell.

### Claim 24 (depends on 23)

The cell of claim 23, which is comprised in a plant.

### Claim 25 (depends on 1)

A method of expressing a heterologous gene in a selected cell comprising introducing a construct of claim 1 into the selected cell.

### Claim 26 (depends on 18)

The method of claim 18, wherein the selected cell is an animal cell.

### Claim 27 (depends on 19)

The method of claim 19, wherein the animal cell is mammalian cell.

### Claim 28

(canceled)

### Claim 29 (depends on 25)

The method of claim 25, wherein the selected cell is selected from mesenchymal, epithelial, neuronal, heart muscle, skeletal muscle, smooth muscle, and embryonic muscle.

### Claim 30 (depends on 27)

The method of claim 27, wherein the cell is comprised in a non-human mammal.

### Claim 31 (depends on 25)

The method of claim 25, wherein the selected cell is a plant cell.

### Claim 32

(canceled)

### Claim 33 (depends on 31)

The method of claim 31, wherein the cell is comprised in a plant.

### Claim 34 (depends on 25)

The method of claim 25, wherein the selected cell is a fungal cell.
